Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

A 50-year-old resident of Cheshire, who mistook his initial symptoms of bladder cancer to be a UTI, drank cranberry juice as ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 ...

This symptom when going to the toilet can be a sign of prostate, bladder or kidney cancer and should "never be ignored".

Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...

At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...